$CLRB
Cellectar Biosciences, Inc.

2019 Q2 Form 10-Q Financial Statement

#000114420419023902 Filed on May 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.390M $1.320M $1.170M
YoY Change 17.8% -0.75% 18.18%
% of Gross Profit
Research & Development $1.810M $2.308M $1.040M
YoY Change 5.04% 8.68% -66.45%
% of Gross Profit
Depreciation & Amortization $40.00K $32.73K $30.00K
YoY Change 300.0% 89.2% -97.62%
% of Gross Profit
Operating Expenses $3.200M $2.308M $2.200M
YoY Change 85.71% 8.68% -46.21%
Operating Profit -$3.630M
YoY Change 5.1%
Interest Expense $10.00K $12.17K $60.00K
YoY Change 136.52% 161.52% 500.0%
% of Operating Profit
Other Income/Expense, Net $8.171K
YoY Change -136.65%
Pretax Income -$3.190M -$3.620M -$3.830M
YoY Change 9.25% 4.02% -6.13%
Income Tax
% Of Pretax Income
Net Earnings -$3.190M -$3.622M -$3.830M
YoY Change 9.22% 4.2% -6.13%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$458.3K -$758.9K -$732.3K
COMMON SHARES
Basic Shares Outstanding 5.315M 4.758M 4.758M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.85M $10.49M $13.26M
YoY Change 303.11% 53.81% 32.47%
Cash & Equivalents $16.85M $10.49M $13.26M
Short-Term Investments
Other Short-Term Assets $1.330M $600.0K $700.0K
YoY Change 58.33% -27.71% 48.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.18M $11.09M $13.95M
YoY Change 262.42% 45.01% 33.21%
LONG-TERM ASSETS
Property, Plant & Equipment $870.0K $516.8K $543.3K
YoY Change 310.44% 124.72% 122.03%
Goodwill $0.00
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $80.00K $6.214K $18.09K
YoY Change -14.06% -37.86% 52.34%
Total Long-Term Assets $960.0K $1.456M $1.102M
YoY Change -51.53% -23.77% -54.03%
TOTAL ASSETS
Total Short-Term Assets $18.18M $11.09M $13.95M
Total Long-Term Assets $960.0K $1.456M $1.102M
Total Assets $19.14M $12.55M $15.05M
YoY Change 173.55% 31.27% 16.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.530M $2.060M $612.0K
YoY Change 21.05% 9.57% -34.41%
Accrued Expenses $100.0K $100.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $2.670M $2.200M $1.622M
YoY Change 16.63% 4.25% -23.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $480.0K $500.0K $170.0K
YoY Change
Total Long-Term Liabilities $480.0K $502.2K $171.0K
YoY Change 84407.04% 7627.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.670M $2.200M $1.622M
Total Long-Term Liabilities $480.0K $502.2K $171.0K
Total Liabilities $3.150M $2.702M $1.793M
YoY Change 37.56% 28.06% -15.3%
SHAREHOLDERS EQUITY
Retained Earnings -$101.2M -$97.59M
YoY Change 15.24% 15.7%
Common Stock $51.00 $47.00
YoY Change 193.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.99M $9.847M $13.26M
YoY Change
Total Liabilities & Shareholders Equity $19.14M $12.55M $15.05M
YoY Change 173.55% 31.27% 16.96%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$3.190M -$3.622M -$3.830M
YoY Change 9.22% 4.2% -6.13%
Depreciation, Depletion And Amortization $40.00K $32.73K $30.00K
YoY Change 300.0% 89.2% -97.62%
Cash From Operating Activities -$2.650M -$2.815M -$2.740M
YoY Change 3.92% -11.58% -3.18%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $6.242K -$380.0K
YoY Change 338.04%
Acquisitions
YoY Change
Other Investing Activities $10.00K
YoY Change
Cash From Investing Activities -$10.00K -$6.242K -$370.0K
YoY Change 338.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.020M -811.0 0.000
YoY Change -10122.22% 11.4% -100.0%
NET CHANGE
Cash From Operating Activities -2.650M -2.815M -2.740M
Cash From Investing Activities -10.00K -6.242K -370.0K
Cash From Financing Activities 9.020M -811.0 0.000
Net Change In Cash 6.360M -2.822M -3.110M
YoY Change -340.91% -11.42% -171.66%
FREE CASH FLOW
Cash From Operating Activities -$2.650M -$2.815M -$2.740M
Capital Expenditures -$10.00K $6.242K -$380.0K
Free Cash Flow -$2.640M -$2.822M -$2.360M
YoY Change 3.53% -11.43% -16.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
604650
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
641218
CY2019Q1 us-gaap Assets Current
AssetsCurrent
11092938
CY2018Q4 us-gaap Assets Current
AssetsCurrent
13951834
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
516847
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
543339
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
51
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
47
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
109267845
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108323208
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101209984
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97588343
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9846974
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
13260961
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12548944
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15054082
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2308397
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2124060
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1321415
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1329467
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
3629812
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
3453527
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3629812
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3453527
CY2019Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-4000
CY2018Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-26950
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
12171
CY2018Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4654
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8171
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22296
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3621641
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3475823
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5086709
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4732387
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.07
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4773500
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1680818
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13310616
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10061421
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
880
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2019Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
47000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
43000
CY2018Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-07-31
CY2018Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1355000
CY2018Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2785000
CY2018Q3 us-gaap Share Price
SharePrice
4.00
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.00
CY2018Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
16560000
CY2018Q3 clrb Net Proceeds From Issuance Or Sale Of Equity After Deducting Underwriting Discounts And Commissions And Related Offering Expenses
NetProceedsFromIssuanceOrSaleOfEquityAfterDeductingUnderwritingDiscountsAndCommissionsAndRelatedOfferingExpenses
15000000
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5318747
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
207654
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
173438
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
425713
CY2019Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
367853
CY2019Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
54689
CY2019Q1 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
3171
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10488288
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13255616
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5086709
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4732387
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Reclassifications</div></div>&#160;&#8212; <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such classifications did not have an overall material effect on the Company&#8217;s financial condition or statement of operations as previously reported. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> &#8212; Financial instruments that subject the Company to credit risk consist of cash and equivalents on deposit with financial institutions. The Company&#8217;s excess cash as of March 31, 2019 and December 31, 2018 is on deposit in interest-bearing transaction accounts with well-established financial institutions. At times, such amounts may exceed the FDIC insurance limits. As of March 31, 2019,&#160;and December 31, 2018, uninsured cash balances totaled approximately $10,000,000 and $12,800,000, respectfully.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
31.74
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4.12
CY2019Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2055074
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1543819
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
783000
CY2019Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company has an option to extend the term of the lease for one additional 60-month period.
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
167430
CY2018Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.61
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
118750
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.99
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
133000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
156000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
159000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
161000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
161000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
13000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
783000
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2018Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
60-month period
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
598000
CY2019Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
10000000
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
12800000
CY2019Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
49425
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
49425
CY2018Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At a special meeting held on July 12, 2018, our stockholders approved an amendment to our certificate of incorporation to affect a reverse split of our common stock at a ratio between 1:5 to 1:10 and authorized the Board to determine the ratio at which the reverse split would be. The Board authorized the ratio of the reverse split, and effective at the close of business on July 16, 2018, the Company implemented a 1-for-10 reverse stock split of its outstanding common stock. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock that the Company is authorized to issue remains unchanged at 80,000,000 and the par value remains at $0.00001 per share. Accordingly, stockholders&#8217; equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.
CY2019Q1 us-gaap Long Term Investments
LongTermInvestments
540823
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
540823
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18086
CY2019Q1 us-gaap Assets
Assets
12548944
CY2018Q4 us-gaap Assets
Assets
15054082
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3184105
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10488288
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6875163
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
28000
CY2018Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option to extend the term of the lease for one additional 60-month period.
CY2018Q4 clrb Deferred Lease Liability
DeferredLeaseLiability
176000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
392122
CY2019Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
47000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
43000
CY2019Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1402
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2213
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
33090
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2199763
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1622122
CY2019Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
170999
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
502207
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
170999
CY2019Q1 us-gaap Liabilities
Liabilities
2701970
CY2018Q4 us-gaap Liabilities
Liabilities
1793121
CY2019Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10754463
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
173438
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
7452078
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
13260961
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
207654
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2019Q1 us-gaap Treasury Stock Retired Par Value Method Amount
TreasuryStockRetiredParValueMethodAmount
0
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9846974
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3475823
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32733
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17301
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
207654
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
173438
CY2019Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-4000
CY2018Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-26950
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
511256
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
16025
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-36568
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-107984
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-11872
CY2018Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
49980
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2815275
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001279704
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
CLRB
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5315209
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
96287
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
502207
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q1 clrb Non Cash Lease Expense
NonCashLeaseExpense
13281
CY2019Q1 clrb Increase Decrease Lease Liability
IncreaseDecreaseLeaseLiability
-10998
CY2018Q1 clrb Increase Decrease Lease Liability
IncreaseDecreaseLeaseLiability
0
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
405000
CY2018Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019Q1 clrb Lease Liability Established Right Of Use Asset
LeaseLiabilityEstablishedRightOfUseAsset
609000
CY2018Q1 clrb Lease Liability Established Right Of Use Asset
LeaseLiabilityEstablishedRightOfUseAsset
0
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6242
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1425
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6242
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1425
CY2019Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
811
CY2018Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
728
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-811
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-728
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2822328
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3186258
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
138619
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
152626
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
155403
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
158235
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
161123
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
13610
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
779616
CY2019Q1 clrb Operating Lease Right Of Use Liability
OperatingLeaseRightOfUseLiability
-598000

Files In Submission

Name View Source Status
0001144204-19-023902-index-headers.html Edgar Link pending
0001144204-19-023902-index.html Edgar Link pending
0001144204-19-023902.txt Edgar Link pending
0001144204-19-023902-xbrl.zip Edgar Link pending
clrb-20190331.xml Edgar Link completed
clrb-20190331.xsd Edgar Link pending
clrb-20190331_cal.xml Edgar Link unprocessable
clrb-20190331_def.xml Edgar Link unprocessable
clrb-20190331_lab.xml Edgar Link unprocessable
clrb-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv519467_10q.htm Edgar Link pending
tv519467_ex31-1.htm Edgar Link pending
tv519467_ex31-2.htm Edgar Link pending
tv519467_ex32-1.htm Edgar Link pending